AlphaFold predicted structure
MOCS1 · Q9NZB8

Mean pLDDT
79.7/ 100
Confident
636 residues
Confidence breakdown
- Very high(≥ 90)61%
- Confident(70–90)14%
- Low(50–70)4%
- Very low(< 50)21%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
molybdenum cofactor synthesis 1
Annotations refreshed 10 hours ago.
Diagnostic Grade (Green)
DDG2P
BIALLELIC, autosomal or pseudoautosomalEarly onset or syndromic epilepsy
BIALLELIC, autosomal or pseudoautosomalFetal anomalies
BIALLELIC, autosomal or pseudoautosomalIntellectual disability
BIALLELIC, autosomal or pseudoautosomalLikely inborn error of metabolism
BIALLELIC, autosomal or pseudoautosomalUndiagnosed metabolic disorders
BIALLELIC, autosomal or pseudoautosomalChildhood onset dystonia, chorea or related movement disorder
sulfite oxidase deficiency due to molybdenum cofactor deficiency type A
sulfite oxidase deficiency due to molybdenum cofactor deficiency
encephalopathy due to sulfite oxidase deficiency
alcohol drinking
neurodegenerative disease
atrial fibrillation
Abnormal toe morphology
complex regional pain syndrome
major depressive disorder
septic shock
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Molybdenum cofactor biosynthesis protein 1
Isoform MOCS1A and isoform MOCS1B probably form a complex that catalyzes the conversion of 5'-GTP to cyclic pyranopterin monophosphate (cPMP) (PubMed:11891227, PubMed:23627491, PubMed:29368224, PubMed:31996372). MOCS1A catalyzes the cyclization of GTP to (8S)-3',8-cyclo-7,8-dihydroguanosine 5'-triphosphate and MOCS1B catalyzes the subsequent conversion of (8S)-3',8-cyclo-7,8-dihydroguanosine 5'-triphosphate to cPMP (PubMed:11891227, PubMed:23627491, PubMed:29368224, PubMed:31996372)
MOCS1 · Q9NZB8

Mean pLDDT
79.7/ 100
Confident
636 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0